Pages that link to "Q51167980"

The following pages link to Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis (Q51167980):

Displaying 25 items.

• Optimizing treatment success in multiple sclerosis (Q26771968) (← links)
• Multiple sclerosis-a quiet revolution (Q26826930) (← links)
• Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS) (Q36008726) (← links)
• Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study (Q36859528) (← links)
• Herding: a new phenomenon affecting medical decision-making in multiple sclerosis care? Lessons learned from DIScUTIR MS (Q37626730) (← links)
• Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS). (Q37672368) (← links)
• FLAIRfusion Processing with Contrast Inversion : Improving Detection and Reading Time of New Cerebral MS Lesions (Q38375704) (← links)
• Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. (Q38723319) (← links)
• The future of multiple sclerosis treatments. (Q38808485) (← links)
• Treatment decisions in multiple sclerosis - insights from real-world observational studies. (Q39022643) (← links)
• Decreased interferon-β induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis. (Q39130808) (← links)
• The transition from first-line to second-line therapy in multiple sclerosis (Q41014662) (← links)
• Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education (Q41488417) (← links)
• A supervised framework with intensity subtraction and deformation field features for the detection of new T2-w lesions in multiple sclerosis. (Q48633006) (← links)
• Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields (Q48206411) (← links)
• Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients (Q48386105) (← links)
• "No evidence of disease activity" - is it an appropriate surrogate in multiple sclerosis? (Q52567799) (← links)
• Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. (Q53069773) (← links)
• Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. (Q53841734) (← links)
• Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists (Q57492439) (← links)
• The Role of Prescribing Generic (Non-proprietary) Drugs in the Prevalence of Therapeutic Inertia in Multiple Sclerosis Care (Q58122615) (← links)
• Comparison of Physician Therapeutic Inertia for Management of Patients With Multiple Sclerosis in Canada, Argentina, Chile, and Spain (Q91954537) (← links)
• A fully convolutional neural network for new T2-w lesion detection in multiple sclerosis (Q92519612) (← links)
• Traffic Lights Intervention Reduces Therapeutic Inertia: A Randomized Controlled Trial in Multiple Sclerosis Care (Q93152475) (← links)
• Identifying responders and nonresponders to interferon therapy in multiple sclerosis (Q97570184) (← links)